Navigation Links
ShangPharma Announces Milestone Achievement in Research Partnership with Hengrui
Date:1/19/2012

SHANGHAI, Jan. 19, 2012 /PRNewswire-Asia/ -- ShangPharma Corporation (NYSE: SHP) ("ShangPharma" or the "Company"), a leading China-based pharmaceutical and biotechnology research and development outsourcing company, today announced that it has reached the first milestone in its strategic partnership with Jiangsu Hengrui Medicine Co., Ltd. ("Hengrui"), a leading Chinese pharmaceutical company, to develop novel therapeutic monoclonal antibodies ("mAbs").

"Achieving this first milestone is an important step forward in our development of therapeutic antibodies," said Dr. Lianshan Zhang, Hengrui's President of Global R&D. "We are pleased that we have achieved this just a few months into our strategic partnership with ShangPharma's biologics division."

"We are delighted that this ground breaking collaboration to develop novel therapeutic monoclonal antibodies in China is rapidly producing results," said Michael Xin Hui, founder and Chief Executive Officer of ShangPharma. "We believe that reaching this strategically important milestone is just the first of many achievements that the relationship between ShangPharma and Hengrui will yield."

The long-term collaborative project includes three additional specific milestone targets. The goal of the strategic partnership is to deliver a drug candidate.

About JiangsuHengrui Medicine Co., Ltd.

Jiangsu Hengrui Medicine Co., Ltd., established in 1970, is a fully integrated pharmaceutical company in China, with net sales of about US$550 million in 2010. The company has been experiencing organic growth at an annual rate of 25% in the past few years. It is recognized as the top innovative home-grown drug company, with over a dozen of new molecular entities in clinical trials and dozens more under pre-clinical development. Hengrui's products and R&D span over multiple therapeutic areas, such as oncology, cardiovascular and metabolic diseases, CNS, inflammation, hematology and anesthesiology. For more information, please visit http://www.hrs.com.cn.

About ShangPharma ShangPharma Corporation is a leading China-based contract research organization providing high-quality and cost-effective services for the pharmaceutical and biotechnology industry. It offers a broad range of high-quality, integrated services across the drug discovery and development process to help international and Chinese pharmaceutical and biotechnology companies discover and develop novel drug candidates efficiently. ShangPharma's services consist of discovery chemistry, discovery biology and preclinical development, pharmaceutical development and biologics services. For more information, please visit www.shangpharma.com.

Safe Harbor: Forward-Looking Statements This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements can be identified by terminology such as "may," "will," "expect," "anticipate," "aim," "estimate," "intend," "plan," "believe," "likely to" or other similar expressions. The Company has based these forward-looking statements largely on its current expectations and projections about future events and financial trends that it believes may affect its financial condition, results of operations, business strategy and financial needs. The quotations from management in this press release contain forward-looking statements. The Company may also make written or oral forward-looking statements in its reports filed or furnished with the U.S. Securities and Exchange Commission, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about the Company's beliefs and expectations, are forward-looking statements and are subject to change, and such change may be material and may have a material adverse effect on the Company's financial condition and results of operations for one or more periods. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained, either expressly or impliedly, in any of the forward-looking statements in this press release. The Company expects to face potential risks and uncertainties related to its ability to, among other things, attract, train, motivate and retain skilled scientists; diversify its customer base and adapt to potential loss of sales to, or significant reduction in orders from, any of its major customers; adapt its business to industry trends, such as fluctuations in the R&D budgets of pharmaceutical and biotechnology industry participants; protect the intellectual property rights of its customers; comply with applicable regulations and industry standards; compete effectively in its industry, which may subject it to increasing pricing pressure and reduce the demand for its services; expand and market its services and manage its growth; and develop and maintain effective internal control over financial reporting; as well as other risks outlined in the Company's filings with the U.S. Securities and Exchange Commission. All information provided in this press release and in the attachments is as of the date of this press release, and the Company does not undertake any obligation to update any such information, except as required under applicable law. For further information, please contact:  ShangPharma Ms. Lan XieVP of Finance and Investor RelationsEmail: ir@shangpharma.com Brunswick GroupJosh GartnerEmail: shangpharma@brunswickgroup.com Phone: 86-10-5960-8600
'/>"/>

SOURCE ShangPharma Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ShangPharma Announces Opening of New Facility to Support Lillys Pipeline
2. ShangPharma to Attend Two Upcoming Investor Conferences
3. ShangPharma Announces Third Quarter 2011 Results
4. ShangPharma Purchases Shanghai In-vivo Drug Research Facility from Charles River
5. ShangPharma Corporation Announces Shareholder Resolutions Adopted at 2011 Annual General Meeting
6. ShangPharma Corporation Announces Resignation of a Director
7. ShangPharma Corporation to Hold 2011 Annual General Meeting on October 14, 2011
8. ShangPharma Announces Up to $10 Million Share Repurchase Program
9. ShangPharmas Biologics Division Announces Accelerated Achievement of Milestones for Two Multi-Stage Projects
10. ShangPharma Corporation to Announce First Quarter 2011 Financial Results on May 19, 2011
11. ShangPharma Corporation Files 2010 Annual Report on Form 20-F
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... DUBLIN , Mar. 24, 2017 Research and ... Size, Share, Development, Growth and Demand Forecast to 2022" report to ... The global ... expected to grow at a CAGR of 6.7% during 2016-2022 ... segment held the largest share in the global market in 2015. Among ...
(Date:3/24/2017)... 24, 2017   The Accreditation Council for ... affairs in the pharmaceutical industry has appointed Dr. ... a newly formed scientific advisory board. Dr. Chin ... the first ever medical affairs think tank within ... about the ACMA, please visit  www.medicalaffairsspecialist.org .  ...
(Date:3/24/2017)... YORK , March 24, 2017 FinancialBuzz.com News ... Medical cannabis products ... View Research, Inc., projects that the global medical cannabis market will reach ... is a major market for the new growing industry. By ... place to legally buy and sell medical cannabis. More conservative states like ...
Breaking Medicine Technology:
(Date:3/24/2017)... ... March 24, 2017 , ... ... Walk with God #TruthwithGrace”: a devotional journal chronicling the writer’s path toward true ... How to Walk with God #TruthwithGrace” is the creation of published author Lea ...
(Date:3/24/2017)... ... ... and Harvest A Cultivation of Christian Love” is the creation of published author, David ... wife, Anna Marie. He and his wife are the proud parents of four grown ... “Shadow and Substance.” , “Love, the agape kind, is seen as more than an ...
(Date:3/24/2017)... ... 2017 , ... “The Adventures of Joey, The Dog Who Barks at Puddles”: ... life to the fullest, as God intended. “The Adventures of Joey, The Dog Who ... grandmother pursuing her passion for writing, especially about truth and human behavior. , Published ...
(Date:3/23/2017)... Boulder, CO (PRWEB) , ... March 23, 2017 , ... ... higher bar for entry into teacher preparation programs. The NCTQ report suggests, based on ... boosting entry requirements would significantly improve teacher quality in the U.S. It argues that ...
(Date:3/23/2017)... ... March 23, 2017 , ... Demonstrating their commitment to ... public health departments have been awarded national accreditation through the Public Health ... the expanding network of communities across the nation whose health departments meet rigorous ...
Breaking Medicine News(10 mins):